Literature DB >> 34067349

Repeated Exposure to Subinfectious Doses of SARS-CoV-2 May Promote T Cell Immunity and Protection against Severe COVID-19.

Maria Laura De Angelis1, Federica Francescangeli1, Rachele Rossi1, Alessandro Giuliani2, Ruggero De Maria3,4, Ann Zeuner1.   

Abstract

Europe is experiencing a third wave of COVID-19 due to the spread of highly transmissible SARS-CoV-2 variants. A number of positive and negative factors constantly shape the rates of COVID-19 infections, hospitalization, and mortality. Among these factors, the rise in increasingly transmissible variants on one side and the effect of vaccinations on the other side create a picture deeply different from that of the first pandemic wave. Starting from the observation that in several European countries the number of COVID-19 infections in the second and third pandemic wave increased without a proportional rise in disease severity and mortality, we hypothesize the existence of an additional factor influencing SARS-CoV-2 dynamics. This factor consists of an immune defence against severe COVID-19, provided by SARS-CoV-2-specific T cells progressively developing upon natural exposure to low virus doses present in populated environments. As suggested by recent studies, low-dose viral particles entering the respiratory and intestinal tracts may be able to induce T cell memory in the absence of inflammation, potentially resulting in different degrees of immunization. In this scenario, non-pharmaceutical interventions would play a double role, one in the short term by reducing the detrimental spreading of SARS-CoV-2 particles, and one in the long term by allowing the development of a widespread (although heterogeneous and uncontrollable) form of immune protection.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; T cell responses; environmental exposure; facial masking; fomites; memory T cells; protective immunity

Mesh:

Year:  2021        PMID: 34067349     DOI: 10.3390/v13060961

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  75 in total

1.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Authors:  Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti
Journal:  Nature       Date:  2020-07-15       Impact factor: 49.962

Review 2.  The virology and immunobiology of lymphocytic choriomeningitis virus infection.

Authors:  M J Buchmeier; R M Welsh; F J Dutko; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

3.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques.

Authors:  Ann J Hessell; Pascal Poignard; Meredith Hunter; Lars Hangartner; David M Tehrani; Wim K Bleeker; Paul W H I Parren; Preston A Marx; Dennis R Burton
Journal:  Nat Med       Date:  2009-06-07       Impact factor: 53.440

Review 4.  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.

Authors:  Alessandro Sette; Shane Crotty
Journal:  Nat Rev Immunol       Date:  2020-08       Impact factor: 53.106

5.  Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.

Authors:  Sin Fun Sia; Li-Meng Yan; Alex W H Chin; Kevin Fung; Ka-Tim Choy; Alvina Y L Wong; Prathanporn Kaewpreedee; Ranawaka A P M Perera; Leo L M Poon; John M Nicholls; Malik Peiris; Hui-Ling Yen
Journal:  Nature       Date:  2020-05-14       Impact factor: 49.962

6.  Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February.

Authors:  Daniel J Grint; Kevin Wing; Elizabeth Williamson; Helen I McDonald; Krishnan Bhaskaran; David Evans; Stephen Jw Evans; Alex J Walker; George Hickman; Emily Nightingale; Anna Schultze; Christopher T Rentsch; Chris Bates; Jonathan Cockburn; Helen J Curtis; Caroline E Morton; Sebastian Bacon; Simon Davy; Angel Ys Wong; Amir Mehrkar; Laurie Tomlinson; Ian J Douglas; Rohini Mathur; Paula Blomquist; Brian MacKenna; Peter Ingelsby; Richard Croker; John Parry; Frank Hester; Sam Harper; Nicholas J DeVito; Will Hulme; John Tazare; Ben Goldacre; Liam Smeeth; Rosalind M Eggo
Journal:  Euro Surveill       Date:  2021-03

7.  Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection.

Authors:  Zhongfang Wang; Xiaoyun Yang; Jiaying Zhong; Yumin Zhou; Zhiqiang Tang; Haibo Zhou; Jun He; Xinyue Mei; Yonghong Tang; Bijia Lin; Zhenjun Chen; James McCluskey; Ji Yang; Alexandra J Corbett; Pixin Ran
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

8.  Viral Dose and Immunosuppression Modulate the Progression of Acute BVDV-1 Infection in Calves: Evidence of Long Term Persistence after Intra-Nasal Infection.

Authors:  Rebecca Strong; Severina Anna La Rocca; David Paton; Emmanuelle Bensaude; Torstein Sandvik; Leanne Davis; Jane Turner; Trevor Drew; Rudiger Raue; Ilse Vangeel; Falko Steinbach
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

9.  Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.

Authors:  Jincun Zhao; Jingxian Zhao; Ashutosh K Mangalam; Rudragouda Channappanavar; Craig Fett; David K Meyerholz; Sudhakar Agnihothram; Ralph S Baric; Chella S David; Stanley Perlman
Journal:  Immunity       Date:  2016-06-07       Impact factor: 31.745

10.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.

Authors:  Carolyn Rydyznski Moderbacher; Sydney I Ramirez; Jennifer M Dan; Alba Grifoni; Kathryn M Hastie; Daniela Weiskopf; Simon Belanger; Robert K Abbott; Christina Kim; Jinyong Choi; Yu Kato; Eleanor G Crotty; Cheryl Kim; Stephen A Rawlings; Jose Mateus; Long Ping Victor Tse; April Frazier; Ralph Baric; Bjoern Peters; Jason Greenbaum; Erica Ollmann Saphire; Davey M Smith; Alessandro Sette; Shane Crotty
Journal:  Cell       Date:  2020-09-16       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.